Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06565611 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
A Phase 2 study of Obesity, sponsored by Palatin Technologies.
- Active
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 4
- Study locations
NCT06565611 is a Phase 2 study of Obesity that is active but no longer recruiting, run by Palatin Technologies. The registered enrollment target is 108 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (87% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT06565611, a Phase 2 study of Obesity, is active but no longer recruiting, sponsored by Palatin Technologies.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with a BMI ranging from 30.0 to 45.0 kg/m2 (inclusive).
Conditions Studied
Interventions
- DRUG tirzepatide
- DRUG bremelanotide
Study Locations (4)
Florida
- University Clinical Research-DeLand LLC, d/b/a Accel Research - DeLand
Oklahoma
- Lynn Health Science Institute - Oklahoma City
South Carolina
- Coastal Carolina Research Center - North Charleston
Tennessee
- Lynn Institute of Chattanooga - Chattanooga
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2024-08-05 |
| Est. Completion | 2025-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06565611
The ClinicalTrials.gov registry entry for NCT06565611 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (87% lower). The listed sponsor is Palatin Technologies, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which tirzepatide is the first listed.
NCT06565611 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Oklahoma, South Carolina.
Frequently Asked Questions
What is clinical trial NCT06565611 about?
NCT06565611 is a clinical study titled "A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity". This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with a BMI ranging from 30.0 to 45.0 kg/m2 (inclusive).
What is the current status of trial NCT06565611?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2024-08-05. Estimated completion is 2025-03-31.
What conditions does trial NCT06565611 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT06565611?
The interventions under investigation include: tirzepatide (DRUG), bremelanotide (DRUG).
Who is sponsoring clinical trial NCT06565611?
This trial is sponsored by Palatin Technologies, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06565611 being conducted?
This trial has 4 study locations across Florida, Oklahoma, South Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.